EUVIMEDEUVIMED entdecken
Crossref

AOC3 Loss Promotes Imatinib Resistance in GIST by Stabilizing HK2 and Enhancing H3K18la‐Driven Myc Transcription

Zhiyuan Guo, Linsen Zhou iD, Zhiqiang Wang, Haohai Jiang, Xinguo Zhu

Molecular Carcinogenesis · 2026

DOI: 10.1002/mc.70084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2026. Verfasst von Zhiyuan Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Imatinib Mesylate, Gastrointestinal Stromal Tumors, Proto-Oncogene Proteins c-myc. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Yancheng Health Commission Medical Research Project (Key Program), General Program of Jiangsu Provincial Health Commission, Yancheng Basic Research Program (Youth Fund).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal stromal tumor (GIST) frequently develops resistance to imatinib (IM). This study identifies AOC3 downregulation as a critical contributor to IM resistance. Analyzing clinical samples and IM‐sensitive/resistant GIST cell lines, we found AOC3 significantly decreased in resistant states. Functionally, AOC3 knockdown promoted IM resistance, enhanced glycolytic activity, and increased lactate production. Mechanistically, AOC3 loss attenuated ubiquitin‐mediated degradation of HK2, stabilizing this glycolytic enzyme and boosting lactate generation. Subsequent histone lactylation, notably at H3K18, enriched at the Myc promoter and stimulated its transcription. Crucially, HK2 overexpression reversed AOC3's suppressive effects on glycolysis, lactylation, Myc expression, and IM resistance. In vivo xenograft models confirmed these findings. We conclude that AOC3 acts as a tumor suppressor by promoting HK2 degradation; its loss triggers a HK2/glycolysis/lactylation/Myc axis driving IM resistance, positioning AOC3 as a promising prognostic biomarker and therapeutic target in GIST.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmImatinib MesylateGastrointestinal Stromal TumorsProto-Oncogene Proteins c-mycHistonesGastrointestinal NeoplasmsHumansAnimalsMiceGene Expression Regulation, NeoplasticCell Line, TumorXenograft Model Antitumor AssaysTranscription, GeneticGlycolysisHexokinase

Stichwörter der Autor:innen

AOC3GISTHK2glycolysisimatinib resistance

Substanzen

Imatinib MesylateProto-Oncogene Proteins c-mycMYC protein, humanHK2 protein, humanHistonesHexokinase

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Department of General Surgery, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, Jiangsu, China.

ORCID-Profile: Linsen Zhou

Förderung

  • Yancheng Health Commission Medical Research Project (Key Program)
  • General Program of Jiangsu Provincial Health Commission
  • Yancheng Basic Research Program (Youth Fund)

Zitieren

APA

Guo, Z., Zhou, L., Wang, Z., Jiang, H., & Zhu, X. (2026). AOC3 Loss Promotes Imatinib Resistance in GIST by Stabilizing HK2 and Enhancing H3K18la‐Driven Myc Transcription. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70084

Vancouver

Guo Z, Zhou L, Wang Z, Jiang H, Zhu X. AOC3 Loss Promotes Imatinib Resistance in GIST by Stabilizing HK2 and Enhancing H3K18la‐Driven Myc Transcription. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70084

BibTeX
@article{Guo2026,
  author = {Guo, Zhiyuan and Zhou, Linsen and Wang, Zhiqiang and Jiang, Haohai and Zhu, Xinguo},
  title = {AOC3 Loss Promotes Imatinib Resistance in GIST by Stabilizing HK2 and Enhancing H3K18la‐Driven Myc Transcription},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  doi = {10.1002/mc.70084}
}
Kostenlos starten →